FBP1 and hepatocellular carcinoma: After inhibition of the CK2 kinase activity with the established CK2 inhibitor CX-4945 or a down-regulation of CK2α and CK2α’ expression by specific siRNAs, for the first time, we noticed a decrease in the gene expression as well as a down-regulation of the phosphatase activity of FBP1 in pancreatic β-cells as well as in hepatocellular carcinoma cells, which finally led to a reduction in glucose secretion.